Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678978 | 1.00 | KMT2A (0.56) | KMT2AEPHX2NR1H4IDO1FABP7 | |
| SCHEMBL29402075 | 1.00 | KMT2A (0.56) | KMT2AEPHX2NR1H4IDO1FABP7 | |
| SCHEMBL1855193 | 0.96 | EPHX2 (0.53) | KMT2AEPHX2NR1H4IDO1 | |
| Benzoic Acid SCHEMBL27028192 | 0.95 | KMT2A (0.56) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL6421736 | 0.91 | KMT2A (0.49) | KMT2AEPHX2NR1H4CASP3 | |
| SCHEMBL3177417 | 0.91 | KMT2A (0.62) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL15948331 | 0.89 | KMT2A (0.53) | KMT2AEPHX2NR1H4FABP7FABP5 | |
| SCHEMBL16256817 | 0.89 | KMT2A (0.52) | KMT2AEPHX2NR1H4FABP7FABP5 | |
| SCHEMBL22498215 | 0.89 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL14247589 | 0.88 | KMT2A (0.60) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| US-20250332290-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-10-30 | — | — | US | disclosed |
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | disclosed |
| US-20250090698-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | INDIAN INSTITUTE OF TECH INDORE (IN) | 2025-03-20 | — | — | US | disclosed |
| US-20240382631-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240350680-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-4374924-A2 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| US-11951190-B2 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| US-11931430-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-6191171-B1 | ANTAGONISTS, USEFUL IN INHIBITION OR PREVENTION OF CELL ADHESION AND CELL-ADHESION MEDIATED PATHOLOGIES; FOR DRUGS FOR TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| EP-1053246-A1 | BETA-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF | MOLECUMETICS, LTD. (US) | 2000-11-22 | — | — | EP | disclosed |
| US-6117896-A | Methods for regulating transcription factors | MOLECUMETICS LTD. (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999041276-A1 | β-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF | MOLECUMETICS LTD. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999026923-A1 | PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0915700-A1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MOLECUMETICS, LTD. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998005333-A1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MOLECUMETICS LTD. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885EPHX2 2207/4885NR1H4 367/4885 |
| US-20240382631-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA1 | KMT2A 2664/4885EPHX2 2835/4885NR1H4 348/4885 |
| US-11951190-B2 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | KMT2A 2664/4885EPHX2 2835/4885NR1H4 348/4885 |
| US-20250090698-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | KLK3, SPAG5, DNPEP | KMT2A 1045/4885EPHX2 2022/4885NR1H4 2884/4885 |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, ACP3 | KMT2A 1063/4885EPHX2 2600/4885NR1H4 954/4885 |
| US-11931430-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | KMT2A 2392/4885EPHX2 2892/4885NR1H4 355/4885 |
| US-20240350680-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA1 | KMT2A 2392/4885EPHX2 2892/4885NR1H4 355/4885 |
| US-20250332290-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | FOLH1, KLK3, PSMA2 | KMT2A 1821/4885EPHX2 2032/4885NR1H4 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.